Hengyi Fu

This paper evaluates the impact of NIH's K23 trial pathway on trial leadership, finding increased K-trial leadership but no significant increase in new trials.

The paper introduces a deep learning framework called DepGPS to model tumor vulnerabilities using graph neural networks and transformers, showing improved prediction of context-specific vulnerabilities and utility in identifying synthetic lethal genes.